Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVAMAINT maintenance study in metastatic colorectal cancer
2019-001875-35Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colorectal adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Time to Treatment Failure. Started Jul 2019; status: active.
02
Drugs
bevacizumab
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-001875-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001875-35.